Medical Oncology

Richard Francis Riedel, MD

Associate Professor of Medicine
Member of the Duke Cancer Institute
Campus mail Dept of Medicine, 25179 Morris Bldg, Durham, NC 27710
Phone (919) 681-8031
Email address richard.riedel@duke.edu

Novel therapies for soft tissue and bone sarcomas

In Their Words

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 2005 - 2007
  • Fellow in Hematology-Oncology, Medicine, Duke University, 2003 - 2004
  • Resident in Medicine, Medicine, Duke University, 2000 - 2003
  • M.D., Thomas Jefferson University, 2000

Grants

Publications

Riedel, R., S. Michels, C. Heydt, J. Siemanowski, C. Kobe, A. Bunck, S. Schäfer, et al. “Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma.” Lung Cancer 133 (July 1, 2019): 20–22. https://doi.org/10.1016/j.lungcan.2019.05.006.

Full Text

Davis, Lara E., Vanessa Bolejack, Christopher W. Ryan, Kristen N. Ganjoo, Elizabeth T. Loggers, Sant Chawla, Mark Agulnik, et al. “Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma..” J Clin Oncol 37, no. 16 (June 1, 2019): 1424–31. https://doi.org/10.1200/JCO.18.02374.

PMID
31013172
Full Text

Michels, Sebastian, Bartomeu Massutí, Hans-Ulrich Schildhaus, Jeremy Franklin, Martin Sebastian, Enriqueta Felip, Christian Grohé, et al. “Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial..” J Thorac Oncol, April 9, 2019. https://doi.org/10.1016/j.jtho.2019.03.020.

PMID
30978502
Full Text

Ray, Emily M., Richard F. Riedel, Thomas W. LeBlanc, Christel N. Rushing, and Anthony N. Galanos. “Assessing the Impact of a Novel Integrated Palliative Care and Medical Oncology Inpatient Service on Health Care Utilization before Hospice Enrollment..” J Palliat Med 22, no. 4 (April 2019): 420–23. https://doi.org/10.1089/jpm.2018.0235.

PMID
30394821
Full Text

Scheffler, Matthias, Michaela A. Ihle, Rebecca Hein, Sabine Merkelbach-Bruse, Andreas H. Scheel, Janna Siemanowski, Johannes Brägelmann, et al. “K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways..” J Thorac Oncol 14, no. 4 (April 2019): 606–16. https://doi.org/10.1016/j.jtho.2018.12.013.

PMID
30605727
Full Text

Abdulla, Diana S. Y., Matthias Scheffler, Vanessa Brandes, Maximilian Ruge, Sabine Kunze, Sabine Merkelbach-Bruse, Lucia Nogova, et al. “Monitoring Treatment Response to Erlotinib in EGFR-mutated Non-small-cell Lung Cancer Brain Metastases Using Serial O-(2-[18F]fluoroethyl)-L-tyrosine PET..” Clin Lung Cancer 20, no. 2 (March 2019): e148–51. https://doi.org/10.1016/j.cllc.2018.10.011.

PMID
30528316
Full Text

Schwartz, Abby J., Richard F. Riedel, Thomas W. LeBlanc, Devi Desai, Carol Jenkins, Ellen Mahoney, Janice Humphreys, and Cristina C. Hendrix. “The experiences of older caregivers of cancer patients following hospital discharge..” Support Care Cancer 27, no. 2 (February 2019): 609–16. https://doi.org/10.1007/s00520-018-4355-2.

PMID
30027328
Full Text

Riedel, Richard F. “Anti-angiogenic therapy for malignant solitary fibrous tumour: validation through collaboration..” The Lancet. Oncology 20, no. 1 (January 2019): 14–15. https://doi.org/10.1016/s1470-2045(18)30745-9.

PMID
30578024
Full Text

Gounder, Mrinal M., Michelle R. Mahoney, Brian A. Van Tine, Vinod Ravi, Steven Attia, Hari A. Deshpande, Abha A. Gupta, et al. “Sorafenib for Advanced and Refractory Desmoid Tumors..” The New England Journal of Medicine 379, no. 25 (December 2018): 2417–28. https://doi.org/10.1056/nejmoa1805052.

PMID
30575484
Full Text

Riedel, Richard F., Robin L. Jones, Antoine Italiano, Chet Bohac, Juliette C. Thompson, Kerstin Mueller, Zaeem Khan, Seth M. Pollack, and Brian A. Van Tine. “Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review..” Cancers (Basel) 10, no. 11 (November 1, 2018). https://doi.org/10.3390/cancers10110417.

PMID
30388821
Full Text

Pages